Finally, we found that cAMP markedly reduced cisplatin-mediated mutagenesis in melanocytes, suggesting that melanocyte-directed cAMP induction may be a useful strategy to reduce risk of secondary melanomas in cisplatin-treated cancer patients, particularly among “high-risk” individuals with inherited defects in MC1R known to predispose to melanomas6,56. This evidence concerns the gene MC1R and cancer.